MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
